Product
Nemolizumab
Aliases
CD14152
14 clinical trials
6 indications
Indication
Atopic DermatitisIndication
DermatitisIndication
AtopicIndication
Prurigo NodularisIndication
Healthy Control ParticipantsClinical trial
A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Nemolizumab in Subjects With Chronic Kidney Disease With Associated Moderate to Severe PruritusStatus: Completed, Estimated PCD: 2024-01-03
Clinical trial
An Open-label Drug-Drug Interaction Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Subjects With Moderate-to-Severe Atopic DermatitisStatus: Completed, Estimated PCD: 2023-06-07
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With NemolizumabStatus: Completed, Estimated PCD: 2023-07-07
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects With Prurigo NodularisStatus: Completed, Estimated PCD: 2022-03-30
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects With Prurigo NodularisStatus: Completed, Estimated PCD: 2022-11-11
Clinical trial
A Randomized, Single-Dose, Open-Label, Parallel-Group Study in Healthy Volunteers to Assess the Relative Bioavailability of a Subcutaneous Dose of Nemolizumab When Administered With Auto-Injector Compared to Dual-Chamber SyringeStatus: Completed, Estimated PCD: 2022-11-11
Clinical trial
A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (Aged 2 to 11 Years) With Moderate-to-Severe Atopic DermatitisStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Prurigo NodularisStatus: Active (not recruiting), Estimated PCD: 2026-10-26
Clinical trial
A Double-Blind, Placebo-Controlled, Randomized Study to Assess the Durability of Effect and Safety of Nemolizumab for 24 Weeks in Subjects With Prurigo NodularisStatus: Completed, Estimated PCD: 2023-09-11
Clinical trial
A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics and Safety of Nemolizumab (CD14152) in Adolescent Subjects (12-17 Years) With Moderate-to-Severe Atopic DermatitisStatus: Completed, Estimated PCD: 2020-08-19
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to or for Whom Cyclosporine A is Not Medically AdvisableStatus: Withdrawn, Estimated PCD: 2023-07-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic DermatitisStatus: Completed, Estimated PCD: 2022-08-11
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic DermatitisStatus: Completed, Estimated PCD: 2022-09-26
Clinical trial
A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Moderate-to-Severe Atopic DermatitisStatus: Active (not recruiting), Estimated PCD: 2026-08-31